Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have no idea what the share structure is much less what is available. They purposely are not filing and were operating fraudulently, even when they were filing, according to the SEC which got them booted off the frikkin pink sheets. Evidently an unknown attorney is taking over and calling the shots while instructing Arthur to use a lot of words and say nothing. Also Arthur may not be able to file without incriminating himself.
There are 2.5B in AS. Bring it back current and raise some capital. What's wrong with this CEO?
Why would any investment group invest in QNTA with Arthur still involved. Today show us, he is living in a fantasy world. This stock will never get out a CE status by the SEC.
They will have money if they strike an investment deal. I don't feel that their products are attractive enough (from an ROI perspective) to persuade Big Pharm to invest in them. They have nothing that is FDA approved, so Big Pharm would need to see monster ROI before they would finance that operation. JMHO.
They have no cash / working capital and he is way over his head!
There are 2.5B in AS. Bring it back current and raise some capital. What's wrong with this CEO?
Only option is the sale of the company!
This going to come back alive again?
QNTA has no money! Selling the company is the only option. It the products work and they have magical cure for cancer, there should be several deep pocket pharmaceutical companies ready to buy them out.
I would also be concerned that any buyout would also entail a massive (undesirable) R/S in order to make the financial statements more attractive. No, I'm willing to be patient.
Good point…. It did seem he said lawyer referenced viable/ value worth keeping on with current pursuits ….
So we wait …. Also a sale wouldn’t necessarily mean it would even bode well for us either … waiting and exercising patience as penny pointed out might actually be the better chance at positive result for us
It does sound like Arthur is in negotiations with a possible investor(s), so they don't want to jeopardize those negotiations. I think it makes sense to let the negotiations with the multiple options they are seeking .....work their course. Patience is sometimes a virtual.
Very simple. Arthur EGO is stopping him from making rational business decisions! There is no other option than to sell the business. I am willing to bet, he has not even tried to market the company!
At least he’s communicating … that’s what you had initially said was needed - I’m glad at least they believe there are still viable forward moves
Arthur, It totally obvious you are living in a fantasy world! How stupid can you be? QNTA has no resources to survive without a buyout. There are no investment groups which will give you dime without taking total control. Being silent to the investment community is totally insane. If you ask investors, I can guarantee the majority of them will tell you to find a buyer now. You have been a total failure at running this business! The only reason your are trying to go back to social media is at my recommendation, this needs to be done alone with consistent press release. Sell this Fucked up company! It's your EGO which has caused most of your issues. Pat
Arthur is never going to learn!
Hello Patrick, I hope you are doing well. Unfortunately, I was under the weather for several days and was not able to respond sooner. I am preparing our Twitter and other social media accounts to keep investors posted on company developments. The company has been advised to withhold issuing press releases until we complete certain stages of the various ongoing projects. We will do our best to keep the investor community updates on these important news. Separately, we believe it is not in the best interest of investors for us to sell the company at this stage, specifically when we have several fundamental options to improve the current situation. We want to explore the available options first, and should things not work out, I will consider your suggestion. Have a great weekend. We’ll be in touch. Sincerely, Arthur
Pretty much...
Consider it dead money? We are way past that. We are buried and a Mass has been provided. We are even past the holy resurrection Friday!!!! The 3rd day? Gone… We are at a miracle level!!! Maybe
Of course it is not the same scenario!!! This is worse than Petlife. He got caught with the SEC, ugly, this time. The sec has been on him since Petlife but he managed to get it into someone else hands. This time, the SEC caught him with his pants down and the sheep in position. Embarrassing moment, make the math: pants down, sheep and the SEC = LAMBO poof
Guess we'll see what happens here. I pretty much at this point consider it dead money. But I do hope it comes back to life and finds a new buyer that can run the business part of it so Arthur can stay in his own lane.
Reminds me of a local chef who was very revered by folks for her tasty food. I had moved into the community around the time she reopened a restaurant. And I became a regular customer cause the food was so good. Come to find out she ran into trouble financially and had to shut down again. It turns out that she had no clue how to run a business and would've been better off having someone else handle the day to day while she did what she does best, cooking some excellent meals. I do miss her place and hope if she comes back again, that it's managed by someone else.
Hoping again for the same with QNTA.
The best thing that can happen is they find a buyer for the company and Arthur concentrates on research and not running the business, Hopefully this is in the final stages of happening. The SEC has to be done in dealing with QNTA. I don't see any investment group giving them a dime without taking full control. Let hope for the best, they do have products which work and are very marketable.
Of course it is not the same scenario!!! This is worse than Petlife. He got caught with the SEC, ugly, this time. The sec has been on him since Petlife but he managed to get it into someone else hands. This time, the SEC caught him with his pants down and the sheep in position. Embarrassing moment, make the math: pants down, sheep and the SEC = LAMBO poof
FYI! Hi Patrick. I am working on next press release. Thank you for reminding. Have a great weekends
I concur with mountain
it’s NOT at all the same scenario.
GLTA
Definitely not!
We actually discussed that situation! It’s a valid point you are making, but this situation is very different.
Petlife shareholders got screwed out of everything if that is any example.
He has not had an epiphany, not his first rodeo...
Believe me! That thought has occurred to me several times. Time will tell! But, just about the potential QNTA has!
The devil will be in the details. Could be great. Or shareholders could get sold out.
Trust me when I am telling you. Arthur is not fool. Nobody is teaching him anything new. Communication is his forte!!! This is not the first time he is going thru this (PetLife LLC) same thing again. Only reason why he’s giving some information is because his lawyers are managing the situation. Yes, him taking some exposure thru a PR is an indication things looking better from the SEC side. I am certain Qnta won’t open its doors again under Arthur M command. This will end up with a merger, adquisición/Buy-out . Over
Talking with Arthur, they have several positive things going on with the company! He has finally realized the importance of communication.
Hmmm, interesting. You were certain on the PR, so I guess, we gotta let time to be the judge on this next Intel of yours. Overall, good move, thank you.
Mountain...thanks for the update! Much appreciated.
Yes, I knew they had issues with marketing when they paid that no-name skateboard fellow to advertise.
Update on yesterdays press release. Late morning today, I had an opportunity to speak with Arthur! Yesterday, I sent Arthur a message on LinkedIn stating my concerns about the lack of information posted in the press release. He asked me to call him today to discuss my message. Some of the things we discussed were how vague the information was on the press release. Arthur agreed completely with my comments. Some of the areas we discussed were the fact they do have new Attorneys representing them who specialize in this industry including mergers and buyouts. The attorneys are the ones who advised on not making too many comments about the progress QNTA has been making in the last few months. In addition, they do have a new CPA / Audit Firm representing them who specializes also in this industry. They were recommended by the new Law Firm. We discussed adding the names of these firms on their web site. He also stated this will be covered in the next press release which should be put out next week. They do have sales on their existing products which have given the funding to cover these expenses. Arthur also stated they are working with an organization which specializes in regulatory and FDA approval processes. This group is working on agreement to be compensated once they accomplish their goals. He also stated they have been meeting with several investment groups and potential buyers. They actually have another meeting tomorrow with one of these potential investors. Arthur realizes for QNTA to succeed, they need to take a different route than they have in the past. It was a good conversation and it was clear he and his team are committed to making the right growth decisions. Look for continuous updates starting real soon. The stock price doesn't even come close to the value of what this organization is worth on the market.
The frikken muscle rub was just proof of concept. There is no plausible explanation for not licensing the polarization process or polarized ibuprofen.
Totally agree on the revenues. But I have lost confidence management can do anything constructive with investment other than go through it and be in the same boat.
Up 800% today. If we could do that every day, we'd be in great shape in a couple of weeks.
In the spirit of the holidays I purchased AELIA muscle rub as gifts for my daughters figure skating coaches
GLTA
That would be sweet!
let’s hope the amazon customers buy the muscle rub and subsequently tell two friends and they tell two friends and so on and so .. ( like the old commercial used to say
Yep....forward progress is dependent on: 1) revenues OR 2) securing financing
Expert market. You have to have your account set up to trade on the grey sheets.
Lot of words. No substance as expected.
Is this thing halted, or are there just no shares available?
I'm not getting my hopes up for 'substance', but we'll see. Thanks
Thanks for the update!!
GLTA
Followers
|
116
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13742
|
Created
|
03/12/18
|
Type
|
Free
|
Moderators |
Quanta for 2021 will be undergoing a name change to be announced shortly as well as Quanta is in the process of expanding its product line from 4 SKUs to 38 by summer. We will also be introducing all new branding with new color schemes, new packaging, and exciting celebrity endorsements for the pain relief products and a newly introduced beauty product line. Quanta will also be working on a men’s cosmetic line in conjunction with one of the celebrity endorsements planned for late 2021. The company has hired an advertising agency to help with the rollout of the new branding expected second quarter 2021. This will work in conjunction with a major push the company is on the path of with some major big box retail chains.
Quanta Basics
Quanta is a cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind Quanta’s polarization process has many potential applications. From potentiating bio-ingredients to produce more-effective carbon-trapping plants to transformative anti-aging solutions Quanta’s technology has the opportunity to upend how commercial products are made and the benefits from them. Already we see multi-trillion-dollar global industries benefiting from Quanta’s technology.
Our proof of concept, Quanta’s market-leading CBD pain-relief rub (“Muscle Rub”), is only the first in a series of paradigm shift products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized active ingredient is more soluble and creates stronger bonds with the body’s receptors. This allows us to enhance ingredients so they work faster and more powerfully without the use of chemical by-products or cellular penetration. Quanta believes this natural solution has nearly limitless applications in the world of plant-based consumer products.
Quanta is involved in ambitious projects that we believe will reshape the next wave of climate science, sustainability, nutrition, and more. Having harnessed the technology of the future, Quanta is dedicated to bringing tomorrow’s health and wellness solutions to the billions in need today.
Discovery Synopsys
Using our product development process and business-to-business and direct-to-consumer sales approaches as a benchmark for future business, we developed the Quanta business model. Our technology’s unique ability to strengthen ingredients renders them more potent without added chemicals or penetrating cells means Quanta is in a first-of-its-kind position in the market. As the world’s first company focused on Quantum Biology we sit in a strong, but unique position in the market.
Our ability to increase ingredient efficacy by up to 500% means we are in a rare position to truly disrupt many areas of material science.
Quanta’s technology renders products superior to any on the market today. A 30% re-purchase rate (on one SKU alone) illustrates consumer appetite for the product.
Upcoming products and ventures will be designed to achieve or surpass this level of consumer benefit and uptake.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1691430/000149315221008846/form10-k.htm
Management Team
Arthur Mikaelian, Ph.D.
Chairman & CEO
One of Dr. Arthur Mikaelian’s greatest scientific contributions and groundbreaking inventions is Quantum Physics and Quantum Biology-based polarization technology, which targets molecular structure of the main ingredients in synthetic medications or natural compounds, leading to the increased potency of liquid and solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284B2 as it pertains to the Polarized Scorpion Venom solution. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), and the master gene’s (ATF3) indirect influence on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of pharmaceutical and nutraceuticals drugs, as well as expanding his interests in cancer and oncology.
Dr. Mikaelian’s education began in 1984 at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological/NeuroPsychology; he then went on to complete his postdoctoral work at Vernadsky. Dr. Mikaelian has broad experience with Quantum Physic and Quantum Biology. He also earned an MBA from the University of Bologna in Italy.
Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer
Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992. After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.
Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory. During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist. While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.
Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals. Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.
Grant Mikaelian
Executive Vice President
In 2013, Mr. Grant Mikaelian began working for an advanced biopharmaceutical company called Medolife. During his employment, he amassed a wide range of skills through managing various departments of the company. As a Marketing Sales Department Manager, he led many successful projects to improve customer experience through website development and design, enhanced customer support, streamlined ordering systems, configuration of B2C/B2B logistics, company rebranding, and preparation of marketing literature and presentations. He was later promoted to Operations Manager, overseeing and optimizing company departments on a larger scale. He was involved in production planning, project management of short and long-term goals, hiring prospective employees and contractors, corporate IT improvements, equipment procurement, international product registrations, due diligence preparation, and financial audits. He came to inspire confidence and began working closely with Dr. Arthur Mikaelian, CEO of Medolife. Soon after, Mr. Mikaelian was further promoted to Chief Business Development Officer. As the CBDO, he worked with existing and potential shareholders, was involved in domestic and international investment opportunities, managed multiple departments, increased company and product awareness, expanded product distribution channels, drafted Press Releases and articles, edited and proofread company literature, and more. Mr. Mikaelian is an organized leader with broad experiences in management and promotion of corporate growth.
Clemente Pascarella
Audit Committee
Christopher Rullan
Attorney for Mexico Division
Eduard Sahakyan
Head of R&D
Dr. Sahakyan started his career at Glendale Community College (GGC) as a lab technician for the biology department. He then pursued a biotechnology major at Pasadena City College (PCC). During his studies he interned at the Pasadena Bio Collaborative (PBC) Incubator as part of the LA Bioscience Hub research outreach program. Dr. Sahakyan worked with multiple companies including UCLA, Amgen and others during his summer internship. Upon completion, he was offered a permanent position at BCN (UCLA research collaborative) where he completed multiple projects, some of them are pending publication. In 2019, Dr. Sahakyan was offered a position in Medolife as a research associate. Within a year he was promoted to head scientist. Throughout this time, Dr. Sahakyan has worked on a number of company projects, which he presented at different local and national conferences. One of his bigger projects is the differentiation of embryonic stem cells into red blood cells. He continuously brings new ideas and initiatives to the company.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |